ITMI20120275A1 - Oligonucleotidi per la modulazione dell'espressione genica e loro usi - Google Patents

Oligonucleotidi per la modulazione dell'espressione genica e loro usi Download PDF

Info

Publication number
ITMI20120275A1
ITMI20120275A1 IT000275A ITMI20120275A ITMI20120275A1 IT MI20120275 A1 ITMI20120275 A1 IT MI20120275A1 IT 000275 A IT000275 A IT 000275A IT MI20120275 A ITMI20120275 A IT MI20120275A IT MI20120275 A1 ITMI20120275 A1 IT MI20120275A1
Authority
IT
Italy
Prior art keywords
seq
oligonucleotide
oligonucleotides
group
gene
Prior art date
Application number
IT000275A
Other languages
English (en)
Italian (it)
Inventor
Luca Montemurro
Roberto Tonelli
Andrea Tortori
Leonardo Venturelli
Original Assignee
Biogenera Societa A Responsabilita Limitata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenera Societa A Responsabilita Limitata filed Critical Biogenera Societa A Responsabilita Limitata
Priority to IT000275A priority Critical patent/ITMI20120275A1/it
Priority to SI201330845T priority patent/SI2817407T1/en
Priority to RU2014138198A priority patent/RU2648140C2/ru
Priority to DK13716415.8T priority patent/DK2817407T3/en
Priority to EP13716415.8A priority patent/EP2817407B1/en
Priority to AU2013223694A priority patent/AU2013223694B2/en
Priority to PT137164158T priority patent/PT2817407T/pt
Priority to KR1020147026837A priority patent/KR101992925B1/ko
Priority to CA2864060A priority patent/CA2864060C/en
Priority to PL13716415T priority patent/PL2817407T3/pl
Priority to SG10201606946YA priority patent/SG10201606946YA/en
Priority to LTEP13716415.8T priority patent/LT2817407T/lt
Priority to US14/379,729 priority patent/US10023867B2/en
Priority to ES13716415.8T priority patent/ES2651147T3/es
Priority to NO13716415A priority patent/NO2817407T3/no
Priority to BR112014020885-9A priority patent/BR112014020885B1/pt
Priority to HUE13716415A priority patent/HUE034846T2/en
Priority to CN201380009360.1A priority patent/CN104169421A/zh
Priority to HK15102407.6A priority patent/HK1201878A1/xx
Priority to IN1493MUN2014 priority patent/IN2014MN01493A/en
Priority to CN202210708144.7A priority patent/CN115216475A/zh
Priority to SG11201404852WA priority patent/SG11201404852WA/en
Priority to RS20171253A priority patent/RS56631B1/sr
Priority to SM20180042T priority patent/SMT201800042T1/it
Priority to JP2014558247A priority patent/JP6333739B2/ja
Priority to PCT/IB2013/051410 priority patent/WO2013124807A2/en
Priority to ARP130100546A priority patent/AR090129A1/es
Publication of ITMI20120275A1 publication Critical patent/ITMI20120275A1/it
Priority to TNP2014000327A priority patent/TN2014000327A1/fr
Priority to MA37342A priority patent/MA35935B1/fr
Priority to CY20171101270T priority patent/CY1120084T1/el
Priority to JP2017237889A priority patent/JP2018078893A/ja
Priority to US16/009,303 priority patent/US10752900B2/en
Priority to AU2018278972A priority patent/AU2018278972A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IT000275A 2012-02-24 2012-02-24 Oligonucleotidi per la modulazione dell'espressione genica e loro usi ITMI20120275A1 (it)

Priority Applications (33)

Application Number Priority Date Filing Date Title
IT000275A ITMI20120275A1 (it) 2012-02-24 2012-02-24 Oligonucleotidi per la modulazione dell'espressione genica e loro usi
BR112014020885-9A BR112014020885B1 (pt) 2012-02-24 2013-02-21 oligonucleotídeo anti-gene de cadeia única e composição
CN201380009360.1A CN104169421A (zh) 2012-02-24 2013-02-21 用于调节基因表达的寡核苷酸及其用途
DK13716415.8T DK2817407T3 (en) 2012-02-24 2013-02-21 OLIGONUCLEOTIDES FOR MODULATING GENEPRESSION AND APPLICATIONS THEREOF
EP13716415.8A EP2817407B1 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
AU2013223694A AU2013223694B2 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
PT137164158T PT2817407T (pt) 2012-02-24 2013-02-21 Oligonucleótidos para modular a expressão génica e as suas utilizações
KR1020147026837A KR101992925B1 (ko) 2012-02-24 2013-02-21 유전자 발현 조절을 위한 올리고뉴클레오타이드 및 그 용도
CA2864060A CA2864060C (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
PL13716415T PL2817407T3 (pl) 2012-02-24 2013-02-21 Oligonukleotydy do modulowania ekspresji genów i ich zastosowania
SG10201606946YA SG10201606946YA (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
LTEP13716415.8T LT2817407T (lt) 2012-02-24 2013-02-21 Oligonukleotidai, skirti genų raiškos moduliavimui, ir jų panaudojimas
US14/379,729 US10023867B2 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
ES13716415.8T ES2651147T3 (es) 2012-02-24 2013-02-21 Oligonucleótidos para modular la expresión génica y usos de los mismos
NO13716415A NO2817407T3 (enExample) 2012-02-24 2013-02-21
SI201330845T SI2817407T1 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and their use
HUE13716415A HUE034846T2 (en) 2012-02-24 2013-02-21 Oligonucleotides for influencing gene expression and their use
IN1493MUN2014 IN2014MN01493A (enExample) 2012-02-24 2013-02-21
RU2014138198A RU2648140C2 (ru) 2012-02-24 2013-02-21 Олигонуклеотиды для модулирования экспрессии генов и их применения
HK15102407.6A HK1201878A1 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
CN202210708144.7A CN115216475A (zh) 2012-02-24 2013-02-21 用于调节基因表达的寡核苷酸及其用途
SG11201404852WA SG11201404852WA (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
RS20171253A RS56631B1 (sr) 2012-02-24 2013-02-21 Oligonukleotidi za modulaciju ekspresije gena i njihova upotreba
SM20180042T SMT201800042T1 (it) 2012-02-24 2013-02-21 Oligonucleotidi per la modulazione dell'espressione genica e loro usi
JP2014558247A JP6333739B2 (ja) 2012-02-24 2013-02-21 遺伝子発現を調節するためのオリゴヌクレオチド及びこれの使用
PCT/IB2013/051410 WO2013124807A2 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
ARP130100546A AR090129A1 (es) 2012-02-24 2013-02-22 Oligonucleotidos para la modulacion de la expresion genica y sus usos
TNP2014000327A TN2014000327A1 (en) 2012-02-24 2014-07-31 Oligonucleotides for modulating gene expression and uses thereof
MA37342A MA35935B1 (fr) 2012-02-24 2014-09-10 Oligonucléotides pour moduler l'expression de gènes et leurs utilisations
CY20171101270T CY1120084T1 (el) 2012-02-24 2017-12-05 Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων
JP2017237889A JP2018078893A (ja) 2012-02-24 2017-12-12 遺伝子発現を調節するためのオリゴヌクレオチド及びこれの使用
US16/009,303 US10752900B2 (en) 2012-02-24 2018-06-15 Oligonucleotides for modulating gene expression and uses thereof
AU2018278972A AU2018278972A1 (en) 2012-02-24 2018-12-13 Oligonucleotides for modulating gene expression and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000275A ITMI20120275A1 (it) 2012-02-24 2012-02-24 Oligonucleotidi per la modulazione dell'espressione genica e loro usi

Publications (1)

Publication Number Publication Date
ITMI20120275A1 true ITMI20120275A1 (it) 2013-08-25

Family

ID=45999941

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000275A ITMI20120275A1 (it) 2012-02-24 2012-02-24 Oligonucleotidi per la modulazione dell'espressione genica e loro usi

Country Status (28)

Country Link
US (2) US10023867B2 (enExample)
EP (1) EP2817407B1 (enExample)
JP (2) JP6333739B2 (enExample)
KR (1) KR101992925B1 (enExample)
CN (2) CN115216475A (enExample)
AR (1) AR090129A1 (enExample)
AU (2) AU2013223694B2 (enExample)
BR (1) BR112014020885B1 (enExample)
CA (1) CA2864060C (enExample)
CY (1) CY1120084T1 (enExample)
DK (1) DK2817407T3 (enExample)
ES (1) ES2651147T3 (enExample)
HK (1) HK1201878A1 (enExample)
HU (1) HUE034846T2 (enExample)
IN (1) IN2014MN01493A (enExample)
IT (1) ITMI20120275A1 (enExample)
LT (1) LT2817407T (enExample)
MA (1) MA35935B1 (enExample)
NO (1) NO2817407T3 (enExample)
PL (1) PL2817407T3 (enExample)
PT (1) PT2817407T (enExample)
RS (1) RS56631B1 (enExample)
RU (1) RU2648140C2 (enExample)
SG (2) SG10201606946YA (enExample)
SI (1) SI2817407T1 (enExample)
SM (1) SMT201800042T1 (enExample)
TN (1) TN2014000327A1 (enExample)
WO (1) WO2013124807A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
US20150152410A1 (en) 2012-05-16 2015-06-04 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
JP2015518710A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
EA201492123A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии семейства генов smn
EA201492122A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
AU2013262699A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating ATP2A2 expression
CN110392581A (zh) * 2016-12-13 2019-10-29 阿姆科学有限公司 用于预防或治疗乙型肝炎的药物组合物
EP4497432A4 (en) * 2022-03-22 2025-07-30 Bion Inc PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
WO2004096826A2 (en) * 2003-04-29 2004-11-11 Universita' Degli Studi Di Bologna Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna)
CN102058535A (zh) * 2010-12-21 2011-05-18 中国人民解放军总医院 叶酸受体靶向的新型脂质体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756301B2 (en) * 1997-08-20 2003-01-09 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
CA2400028A1 (en) * 2000-02-14 2001-08-23 Arthur P. Bollon Libraries of optimum subsequence regions of mrna and genomic dna for control of gene expression
JP2004524371A (ja) * 2001-04-13 2004-08-12 ザ・ポピュレイション・カウンシル，インコーポレイテッド 核レセプターを介するペプチド核酸の細胞核内導入
WO2002092617A1 (en) 2001-05-17 2002-11-21 Avi Biopharma, Inc. Combined approach to treatment of cancer using a c-myc antisense oligomer
WO2005045032A2 (en) * 2003-10-20 2005-05-19 Sima Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
RU2007119313A (ru) * 2004-10-25 2008-11-27 Новартис АГ (CH) Полинуклеотиды и полипептиды torc и способы применения
CA2631931C (en) * 2005-12-01 2014-04-29 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
US7625874B2 (en) * 2006-04-11 2009-12-01 The Regents Of The University Of California Compositions and methods for treating diseases associated with T-box and N-Myc
US20080038783A1 (en) * 2006-06-29 2008-02-14 Applera Corporation Compositions and Methods Pertaining to Guanylation of PNA Oligomers
WO2009009739A2 (en) * 2007-07-12 2009-01-15 Theracrine, Inc. Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer
US20110105422A1 (en) * 2008-02-05 2011-05-05 Gary Acton Use of g-rich oligonucleotides for treating neoplastic diseases
KR101866152B1 (ko) * 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
WO2004096826A2 (en) * 2003-04-29 2004-11-11 Universita' Degli Studi Di Bologna Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna)
CN102058535A (zh) * 2010-12-21 2011-05-18 中国人民解放军总医院 叶酸受体靶向的新型脂质体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDREA FACCINI ET AL: "Circular dichroism study of DNA binding by a potential anticancer peptide nucleic acid targeted against the MYCN oncogene", CHIRALITY, vol. 20, no. 3-4, 1 March 2008 (2008-03-01), pages 494 - 500, XP055039940, ISSN: 0899-0042, DOI: 10.1002/chir.20489 *
BRAASCH D A ET AL: "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design", NUCLEIC ACIDS RESEARCH, vol. 30, no. 23, 2002, pages 5160 - 5167, XP002290400, ISSN: 0305-1048, DOI: 10.1093/NAR/GKF651 *
CHRISTENSEN U ET AL: "Stopped-flow kinetics of locked nucleic acid(LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions", BIOCHEMICAL JOURNAL, vol. 354, no. 3, 15 March 2001 (2001-03-15), pages 481 - 484, XP002971047, ISSN: 0264-6021, DOI: 10.1042/0264-6021:3540481 *
DATABASE WPI Week 201157, Derwent World Patents Index; AN 2011-H27774, XP002684911 *
NAGAHAMA K ET AL: "Nuclease resistant methylphosphonate-DNA/LNA chimeric oligonucleotides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 10, 15 May 2009 (2009-05-15), pages 2707 - 2709, XP026085948, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2009.03.116 *
PESSION A ET AL: "TARGETED INHIBITION OF NMYC BY PEPTIDE NUCLEIC ACID IN N-MYC AMPLIFIED HUMAN NEUROBLASTOMA CELLS: CELL-CYCLE INHIBITION WITH INDUCTION OF NEURONAL CELL DIFFERENTIATION AND APOPTOSIS", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 24, no. 2, February 2004 (2004-02-01), pages 265 - 272, XP009045755, ISSN: 1019-6439 *
ROSSI JOHN J: "Transcriptional activation by small RNA duplexes", NATURE CHEMICAL BIOLOGY, vol. 3, no. 3, 1 March 2007 (2007-03-01), pages 136 - 137, XP002548638, ISSN: 1552-4450, DOI: 10.1038/NCHEMBIO0307-136 *

Also Published As

Publication number Publication date
AU2018278972A1 (en) 2019-01-17
SG11201404852WA (en) 2014-10-30
RU2648140C2 (ru) 2018-03-22
TN2014000327A1 (en) 2015-12-21
KR101992925B1 (ko) 2019-06-25
CA2864060A1 (en) 2013-08-29
HUE034846T2 (en) 2018-03-28
LT2817407T (lt) 2018-01-25
WO2013124807A3 (en) 2013-12-27
SMT201800042T1 (it) 2018-03-08
US10023867B2 (en) 2018-07-17
BR112014020885B1 (pt) 2020-10-27
ES2651147T3 (es) 2018-01-24
JP2018078893A (ja) 2018-05-24
NO2817407T3 (enExample) 2018-02-03
US20180282731A1 (en) 2018-10-04
US10752900B2 (en) 2020-08-25
EP2817407B1 (en) 2017-09-06
EP2817407A2 (en) 2014-12-31
US20160040166A1 (en) 2016-02-11
PL2817407T3 (pl) 2018-03-30
IN2014MN01493A (enExample) 2015-04-17
AU2013223694A1 (en) 2014-09-25
AR090129A1 (es) 2014-10-22
KR20140130514A (ko) 2014-11-10
CN104169421A (zh) 2014-11-26
MA35935B1 (fr) 2014-12-01
RS56631B1 (sr) 2018-03-30
SG10201606946YA (en) 2016-10-28
RU2014138198A (ru) 2016-04-10
WO2013124807A2 (en) 2013-08-29
SI2817407T1 (en) 2018-01-31
CA2864060C (en) 2020-03-10
BR112014020885A2 (pt) 2018-01-09
AU2013223694B2 (en) 2019-01-03
DK2817407T3 (en) 2017-12-18
CY1120084T1 (el) 2018-12-12
CN115216475A (zh) 2022-10-21
JP6333739B2 (ja) 2018-05-30
JP2015513398A (ja) 2015-05-14
HK1201878A1 (en) 2015-09-11
PT2817407T (pt) 2017-12-07

Similar Documents

Publication Publication Date Title
US10752900B2 (en) Oligonucleotides for modulating gene expression and uses thereof
JP2023518970A (ja) 安定性の向上を有する修飾オリゴヌクレオチドの合成
JP2022528840A (ja) 安定性が増加した修飾オリゴヌクレオチド
CA3174079A1 (en) Synthetic oligonucleotides having regions of block and cluster modifications
HK1214301A1 (zh) 治療epas1相關疾病的有機組合物
JP2024523466A (ja) ＩＦＮ－γシグナル伝達経路の調節のためのオリゴヌクレオチド
US20240254490A1 (en) Short Duplex DNA as a Novel Gene Silencing Technology and Use Thereof
JP2024535869A (ja) Ｗｆｄｃ２の発現を調節するアンチセンス化合物
WO2012100172A2 (en) Methods and compositions for the specific inhibition of hif-1a by double stranded rna
AU2005270917A1 (en) Gastrin-specific interfering RNA
CA2887461A1 (en) Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases
Gewirtz Nucleic Acid-Based, mRNA-Targeted Therapeutics for Hematologic Malignancies
JP2025542580A (ja) 遺伝子サイレンシング技術としての、デオキシリボヌクレオチドが散在している短鎖二重鎖ｒｎａ、およびその使用
CN111615558A (zh) 用于调节erc1表达的寡核苷酸